Baseline Findings from Dual-Phase Amyloid PET Study in Newly Diagnosed Multiple Sclerosis: Exploring Its Potential as a Biomarker of Myelination and Neurodegeneration.

J Pers Med · 2025 · PMC12653326 · PMID 41295222

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

SUVRmax tends to decrease from eFBB to sFBB, which would be the expected evolution considering the tracer’s pharmacokinetics, with lower SUVR in sFBB likely reflecting greater demyelination [ 9 , 15 ] In contrast, both SUVRmean and SUVRmin exhibit an increasing trend from eFBB to sFBB.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.